This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk11: Ladies and gentlemen, thank you for standing by and welcome to the 10X Genomics third quarter 2020 earnings conference call. At this time, all participants' lines are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star then one on your telephone. Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today, Mr. Eric Jaschke, Director of Investor Relations and Strategic Finance. Thank you. Please go ahead, sir.
spk12: Thank you. Earlier today, 10X Genomics released financial results for the third quarter ended September 30th, 2020. If you have not received this news release, or if you would like to be added to the company's distribution list, please send an email to investors at 10xgenomics.com. An archived webcast of this call will be available on the investor tab of the company's website, 10xgenomics.com, for at least 45 days following this call. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements invoke material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release to Next Genomics issued today. and in the documents and reports filed by 10X Genomics from time to time with the Securities and Exchange Commission. 10X Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. Joining the call today are Serge Saxinov, our CEO and co-founder, and Justin McInerney, our Chief Financial Officer. In addition, Brad Crutchfield, our Chief Commercial Officer, will be available for Q&A. With that, I'll now turn the call over to Serge.
spk07: Thanks, Eric. Good afternoon, and thank you for joining our call to review our third quarter 2020 results. On today's call, I will start with a review of our financial performance during the third quarter. Next, I will discuss some strategic and operational highlights, including updates on recent product launches and acquisitions. I will also discuss the opportunities that lie ahead and how we're planning and investing to capture those opportunities. I will then turn the call over to Justin for a more detailed look at our financials, including detail on the trends we're seeing within our customer base. Starting with our third quarter results, revenues grew to $71.8 million, up 17% year over year, and up 67% sequentially. The strong growth this quarter was driven primarily by an improved operating environment, as many labs around the world continue to reopen for general research. Demand for instruments remained high during the quarter, and we saw a rebound in utilization of consumables as more customers returned to the lab. The increase from the prior quarter was primarily due to the rebound in general research demand. Overall, in the face of a challenging operating environment, we have made incredible progress thus far in 2020. At the beginning of the year, we laid out our key priorities to drive near-term execution, scale the company and invest ambitiously for the future. While this year has turned out much differently than anyone expected, we continue to execute on our strategic goals and have laid the groundwork for an expanded set of long-term opportunities. In addition to strong commercial and operational execution, we achieved a number of important milestones this year, including multiple product launches, the completion of our follow-on offering, the announcement and closing of two acquisitions, and the opening of our manufacturing facilities in Singapore. Our vision is based on the premise that this is the century of biology, in which many of humanity's most pressing health challenges will be solved with precision diagnostics, targeted therapies, and cures to currently intractable diseases. In order to make this future a reality and take advantage of the resulting opportunities, we need to build tools that will accelerate our understanding and mastery of the underlying biological systems. Tools that can measure biology at scale and resolution that matches its massive complexity. Since the start of the single cell revolution a few years ago, it has become increasingly clear that cell heterogeneity intertwined with complex gene networks is a pervasive feature of all human tissues. The future of biological analysis, whether for research or clinical applications, lies with multiplex multi-omics measurements performed at large scale with single cell context. We have designed our product platforms to enable this future. Our Chromium and Visium platforms provide the means for measuring biology at high resolution and scale. We will also develop our future platform around in situ analysis based on a similar vision and to complement our existing platforms. These three approaches should become essential across a wide range of applications in the coming years and beyond. Now, starting with Chromium, the vision for the platform and the value it delivers is being increasingly validated in the market. Demand for our Chromium platform continues to expand rapidly. We are encouraged with the pace of utilization as existing customers have come back into the lab and are especially pleased by the impressive influx of new customers coming into the 10x single-cell ecosystem. It is easy to forget that our Chromium single-cell products have been on the market for only four years, and there are already nearly 2,000 scientific publications that have made use of our technology. The pace of these publications, as well as the breadth of studies they describe, speaks to the fundamental importance of single-cell approaches and underscores the vast potential of the Chromium platform. Last quarter, there have been many great studies that use 10X across a range of fields, including oncology, immunology, neuroscience, infectious diseases, as well as many others. Here, I would like to highlight one paper from researchers at Stanford University and the University of Pennsylvania who sought to understand the reasons for neurotoxicity that's a common side effect of B-cell targeting immunotherapies. Using chromium, the scientists discovered that the target gene for these therapies is also expressed in a small subset of cells in the brain. This finding has important scientific implications, and it demonstrates the crucial value of single-cell analysis for developing new medicines. We executed against our ambitious product roadmap throughout the year and introduced a number of breakthrough products on the Chromium platform thus far in 2020. We launched our targeted gene expression product and a new version of the CellRanger analysis software in the second quarter. In the third quarter, we launched our next generation immune profiling solution and our gene expression Placitaxix multi-ome solution. We have been very encouraged by the initial response to these products. We launched version two of the immune profiling solution in July to provide a number of performance improvements over the previous version. The immune profiling product allows large-scale sequencing of paired immune cell receptors together with multi-omic profiling of the immune cells. The new version detects more receptor pairs and delivers significantly higher gene detection sensitivity, yielding more insights with more efficiency. Since launch, the rate at which customers have been adapting the new immune profiling solution has been impressive and ahead of our expectations. Most customers have been switching to the new version without running head-to-head comparisons that are customary during similar upgrade cycles. This speaks to our reputation in the marketplace and the trust the customers now put in the 10X brand. Moving now to the multi-ome gene expression and ataxic solution. The ability to profile the epigenome and the transcriptome from the same cell across large numbers of cells has been the number one request from our customers over the past two years. The reason this capability has been of such intense interest to scientists is that it provides a path to decipher the rules of epigenetic programming, which has been the holy grail of epigenetic research. With Multium, for the first time ever, researchers now have access to a commercial solution that can answer these questions by measuring gene expression and epigenetic programming simultaneously from the same cell across thousands of cells in parallel. Since its launch in September, this product has drawn lots of interest from our current customers, but also from the epigenetic community more broadly. We're happy to say that it has exceeded our expectations to date. The development of the Multium product was an incredible achievement for the 10X team and is a great example of our competitive advantage. It relied on a number of breakthroughs across multiple disciplines, and was only made possible by the tight multidisciplinary collaboration and the depth of expertise we have assembled across the company. The development of Valtium resulted in a dozen patent applications. Our internal expertise, together with our customer insights, helped us gain early conviction to invest aggressively in this effort. And all of this has now resulted in a highly differentiated product that is having immediate and powerful resonance with the market. Overall, we remain very early in market penetration for chromium, and we're excited about the growing breadth of researchers who are interested in single-cell approaches. Our goal is to keep accelerating broad adoption of our products as we move past the early technologies to the tens of thousands of biologists spanning different fields of study and different types of expertise. We plan to invest broadly in this vision through market development and product innovation. And as single-cell approaches make their way to labs more broadly, solving analytical bottlenecks is becoming an essential part of the customer experience. With this in mind, we recently launched limited access to our 10x cloud analysis platform. This platform includes secure collaboration tools, scalable storage, and compute infrastructure, and provides our customers with the best possible speed and ease of use when running analysis pipelines for gene expression and for immune profiling. These core capabilities come at no additional cost to our customers, which helps to lower the barriers of adoption and democratize single-cell analysis. This is an exciting extension of our highly differentiated software tools from the native environment into the cloud, and this is just the start. Over time, we will continue to add more features and more capabilities. Moving on to Visium. We continue to be impressed by the level of adoption we have seen since we launched this product less than a year ago. The number of new Visium customers continued to grow during the third quarter. Yet even with this influx of new customers, repeat Visium customers for the first time made up the majority of the Visium business, as many of our earlier adopters are increasingly progressing from pilot programs to larger experiments and larger projects. Underscoring this progress are more than 50 publications and preprints describing studies that have made use of the Visium technology today, with many of these being published within the last few months. We're encouraged by the breadth and the pace of these publications. They validate the high-value Visium experiments and demonstrate the ability of our customers to progress through the workflow successfully and make meaningful discoveries. Just as we experienced with single-cell, we believe these papers will drive broad market adoption and are an indicator of future demand. These publications have featured a variety of applications, most notably in oncology and neuroscience, but now in more new areas as well. For example, just recently, in Nature, researchers used Visium in conjunction with chromium-based analysis to study acute respiratory distress syndrome, known as ARDS, in influenza patients. In this study, researchers uncovered a new special state of fibroblast cells and the mechanisms through which they drive the overall response by the immune system. This finding suggests a new potential approach to develop therapies to preserve lung function and improve clinical outcomes. Overall, Visium is very early in its lifecycle, and we're making extensive investments in market development and product development to drive adoption of the platform. In the second quarter, we launched IHC compatibility with Visium, allowing whole transcriptome spatial analysis and immunofluorescence protein detection to be performed in the same tissue. In October, we also launched our targeted gene expression on Visium. This case of product introductions will continue to next year and beyond. Development of the Visium FFPE solution remains on schedule. We are preparing to launch that product in the first half of 2021. And while we aren't ready to give exact product details at this time, the early performance data we have seen to date has exceeded our expectations. We have many other products in development and are very excited about our Visium roadmap. And while both Chromium and Visium remain early in their adoption, looking further out to the future, we have identified in-situ analysis as a logical next step following in the footsteps of our existing platforms. To that end, We were excited to announce the acquisitions of RITCOR and CARTANA, which combined with our early work in this area will form the foundation for the development of our third product platform in the emerging in situ field. In situ analysis refers to the sequencing or measurement of large numbers of different molecules, including RNA, DNA, and proteins directly in their native tissue and with subcellular resolution. This is unlike most current analytical techniques, which require that molecules be removed from tissue before measurement and analysis. In situ approaches entail developing an integrated system with capabilities that are highly complementary to both chromium and visium. In situ methods have analogs with an existing IHC or FISH-based pathology workflows, but offer much higher levels of multiplexing and vastly greater amounts of biological information. We believe that this technology will enable powerful molecular analysis tools which will support discoveries made by the Chromium and Vision platforms, broaden the range of customers, and enable new translational and clinical applications. Based on our in-depth assessment of the C2 landscape and our own internal R&D efforts, we determined that acquiring the RIT Core at Cortana was the right path to address this compelling opportunity. With these acquisitions, Tenex gained key technological advances, teams with deep expertise and talent, as well as a comprehensive intellectual property portfolio, including over 110 foundational patents covering a variety of in situ approaches. As we look to the future, we anticipate that most tissue samples will be analyzed using at least one of these approaches, chromium, visium, or in situ, whether for basic science research or for clinical applications. And while our existing platforms have already been adopted by large numbers of customers, it is important to remember that we're still very early in Chromium market penetration and even earlier with Visium. We continue to be excited by the rapid adoption of Chromium and are highly encouraged by the early trajectory of Visium. And we intend to invest aggressively in both platforms to fully realize their potential. In parallel, will invest in in situ over the coming years to create a new platform with performance and the user experience that 10X customers have come to expect. Since our IPO, we have laid the groundwork to position ourselves to take advantage of the vast opportunities we see unfolding in the coming decade. As we move into 2021, we will continue to invest across our business to realize the full potential of these opportunities. This includes investments in R&D to continue our rapid pace of product development and innovation across all of our platforms, in intellectual property to protect our products and scientific advancements, in our commercial organization to continue to build our sales and service infrastructure and adequately address the interest we're seeing from a variety of markets, including biopharma and translational. And finally, in our operational capabilities to make sure that we have the foundation to support our future growth. As we sit here today, I have more confidence than ever in our strategy. I strongly believe that the resolution and scale of ultra-bio products will be essential in helping to understand biology and advance human health. The interest and excitement for our products reinforce our conviction in our mission and in the vast opportunities that lie ahead for 10X, both now and well into the future. With that, I will now turn the call over to Justin for more detail on our financials.
spk02: Thank you, Serge. Total revenue for the three months ended September 30, 2020, was $71.8 million compared to $61.2 million for the prior year period, representing a 17% increase year over year. Consumables revenue was $60.6 million, which increased 22% over the prior year period. Instrument revenue was $9.7 million, which decreased 7% over the prior year period. Service revenue was $1.6 million, which increased 46% over the prior year period. The increase in consumable revenue this quarter was primarily driven by growth in the instrument install base. though this was partially offset by decreased demand due to lab closures related to COVID-19. Instrument revenue was primarily impacted by lower instrument placements during the quarter, though partially offset by a slightly higher ASP due to shipments of Chromium Connect. Service revenue increased due to a larger number of instruments coming off of their initial one-year warranty and on to paid service contracts. North America revenue for the third quarter was $42.4 million, which increased 18% over the prior year period. EMEA revenue for the third quarter was $15.5 million, which increased 28% over the prior year period. APAC revenue for the third quarter was $14 million, which increased 6% over the prior year period. We saw modest improvements in both the academic and biopharma markets throughout the quarter as researchers continued to return to the lab. We ended the second quarter with approximately 60% of our accounts open for general research. And at the end of the third quarter, we estimated that the number of customer labs open to general research increased to approximately 80%, with many operating at a reduced capacity. Currently, we estimate that approximately 85% of customer labs are open for general research in varying capacities. Now, turning to the rest of the income statement. Gross profit for the third quarter was $57.4 million compared to a gross profit of $45.7 million for the prior year period. Gross margin for the third quarter was 80% compared to 75% for the prior year period. The gross margin increase was primarily driven by lower accrued royalties related to ongoing litigation. Total operating expenses for the third quarter were $122.7 million, an increase of 124% from $54.8 million for the third quarter of 2019. This includes a $40.6 million charge to in-process research and development expense resulting from the CARTANA acquisition. Outside of the charge related to CARTANA, the increase in operating expenses was primarily attributable to increased personnel-related expenses due to ongoing expansion within R&D in the commercial organizations, including stock-based compensation, increased legal expenses, and expenses related to our ongoing COVID-19 employee testing program. R&D expenses for the third quarter, excluding the charge related to Cortana, were $30.1 million compared to $22.2 million for the third quarter of 2019. This was driven primarily by $5.5 million of increased personnel-related expenses, including stock-based compensation, and a $1.6 million increase in expenses related to lab materials, supplies, and equipment. SG&A expenses for the third quarter were $51.5 million compared to $32.6 million for the third quarter of 2019, with the increase driven primarily by $9.6 million of increased personnel-related expenses, including stock-based compensation, and $7.6 million of increased legal expense. Operating loss for the third quarter was $65.3 million compared to a loss of $9.1 million for the third quarter of 2019. This includes $13.8 million of stock-based compensation for the third quarter of 2020 compared to a $3.9 million stock-based compensation expense for the third quarter of 2019. Net loss for the period with $65.8 million compared to a net loss of $9.6 million for the third quarter of 2019. We ended the quarter with $769 million in cash and cash equivalents, which includes net proceeds of $482 million from our September follow-on offering and is net of restricted cash. While we are encouraged by the results this quarter, there remains near-term uncertainty related to COVID-19, and as such, we will refrain from reinstating guidance at this time. However, as we did last quarter, we would like to offer some color on quarterly trends today. As of the end of last week, our overall orders for the fourth quarter are trending approximately 35% up from the fourth quarter of 2019. While we are generally optimistic, this represents our best view of the business as we stand here today. It does not contemplate the impact of rising case counts potentially leading to increased shutdowns or reduced customer lab capacity. And neither does it contemplate the potential for customers to exhaust higher than normal budgets at year end or increase in lab capacity if the situation improves. Turning to cash flow for the fourth quarter, we expect several one-time expenditures, beginning with the payment of $100 million in cash upon closing of the reed core acquisition, our $30 million payment for the land acquisition in Pleasanton, and potential litigation-related payments. At this point, I'll turn it back to Serge.
spk07: Thanks, Justin. Before we wrap up the call, I want to thank everyone at 10X for your continued dedication and incredible efforts this past quarter. Despite numerous obstacles and challenges, you have executed superbly and achieved a remarkable number of key milestones in just a few short months. Looking ahead, we're now in a better than ever position to execute on our ambitious mission. We remain committed to building and commercializing technologies needed to accelerate the Master of Biology and advance human health. With that, we will now open it up for questions. Operator?
spk11: Thank you. As a reminder, to ask a question, you will need to press star, then 1 on your touch-tone telephone. To withdraw your question from the queue, please press the pound key. Please stand by when we compile the Q&A roster. Our first question comes from Tycho Peterson with JP Morgan. Your line is now open.
spk06: Hey, good afternoon. I'll start with ReadCore. I'm just wondering if you could talk a little bit about optimizing the technology. Throughput is one issue I think that's been flagged as something that needs to be improved on. So where do you think throughput can go? And then, you know, are there ways you could leverage the sequencer as well on the back end, you know, beyond kind of the fully integrated system? In other words, could it be decoupled and, you know, partnered up with Chromium at some point?
spk07: So it's too early to talk about specifics of product configuration and specifications. At this point, we're very much focused on integrating the teams and the and the technologies across the three different sides, 3Core, Cortana, and 10X. We certainly, as I've indicated, we're very excited about the potential of the technology and what it can do, and feel pretty bullish, especially in the long term, of addressing whatever concerns people might bring up around this technology. You know, we will update the market as you know in the future as as we proceed through integration and once we kind of have a Established integrated the the teams into our product development process I think it's too early to talk about sort of anything on the backend sequencing or configurations around chromium and the rest of them
spk06: Okay, and then I'm wondering if you could just talk to interest, you know, for the base business from translational, you know, customers, you know, post the IHC launch and, you know, how you think about that kind of market playing out?
spk07: So, yeah, I mean, we are very excited about the market and certainly the traction and translational, the interest in the translational side of the business. We have talked about previously about our – clinical translational research network. So it's a set of customers have come to us, we've formed to promote the use cases and teach each other use cases with translational framework. The biggest probably requirement within that market is FFPE compatibility. And that's certainly something that we're working on and excited by the progress and that's coming next year like we've said. But overall, in the long run, Right now, and kind of as we look to the long run, it looks very promising, both the level of interest now and the level of excitement about the future of the platform.
spk06: Okay, and the last one for Justin. If I kind of look at kind of how things have progressed here, you know, you're down, you know, 30% or so in the second quarter, and then, you know, a flattish in July, and then, you know, 17% for the third quarter applies a big September acceleration. So can you maybe just talk to kind of momentum here? coming out of the quarter? I know you talked about lab accessibility and the percentage of sites that are open, but as we see cases going back up, I guess what's the risk of things slowing a bit here versus the momentum you saw in September?
spk02: So we closed Q3 with about 80% of customers open. And as of right now, we're at about 85%. So there is some positive momentum towards openings. But as of late, we have seen the case counts continue to rise. So there is some uncertainty as to how this will play out over the next few weeks. So I think that there's the potential downside of perhaps the openings reversing and having some closures. But there's also the upside of customers having the normal seasonal year-end closures budget expenditures or the seasonality increase that we typically see in most years. And so we'll have to see how those two factors play out as we close out the year.
spk08: Hey, Tycho, this is Brad. Maybe I'll just give you a little bit of color on the UK because that's one that has gone into a more austere sort of mode of shutdown. And I think we're seeing this across Europe in general is the labs are not shutting down, although there are severe restrictions on social engagements, restaurants, things like that. But the labs and the schools are staying open. And I think there's been a fair amount of work to see that there isn't a lot of spread within the labs, given the fact that PPE is really the normal within these environments. Okay. That's helpful.
spk11: Thanks. Thank you. Our next question comes from Derek DeBruin with Bank of America. Your line is now open.
spk09: Hey, thanks. This is Mike Riskin on for Derek. Appreciate the questions. I'll start with Visium. You provided some interesting color there on, you know, reorders comprising the majority of demand in the quarter for the first time. But could you give us a little bit more color on, you know, sequential growth from 1Q to Q into 3Q? You know, how many customers are ordering now? And also, is Visium... sort of helping you penetrate beyond that traditional Chromium install base? Are you starting to see some additional customers coming in, or is there still mostly a lot of overlap there?
spk07: In terms of, I'll answer the last question first, definitely continuing to see very nice influx of new to 10x customers. In fact, I would say the fraction might have grown this past quarter. And these are, again, kind of going back to Taiko's question, translational kind of oriented researchers, I think it's kind of driving a lot of this interest coming to our ecosystem. So that sort of trajectory is still there and is as strong as it was before, if not stronger. And in terms of kind of the usage, the sequential, yeah, I mean, the platform is growing, definitely increasing in interaction. It's a little... Yeah, the last few quarters have been a little bit hard to analyze again because of COVID and because this is a new product, but definitely growing and growing very nicely. So, yeah, overall is good and the trajectory, especially going to next year, looks really promising.
spk09: Okay. And then, Justin, maybe one for you, especially following the secondary offering this quarter, over almost $800 million on the balance sheet, even after some of the deals you did in the quarter. So clearly a lot of focus in the prepared remarks on investing in the business. but it seems like you're more than well enough capitalized for that. So is there incremental spend beyond what we've been, you know, modeling previously? Which particular areas are you focusing on to sort of add to above and beyond? And then could you give a little bit more color about additional platforms or verticals where you could expand inorganically through M&A, you know, following on the investment in and see-through?
spk02: Hey, Mike, good question. The investments in R&D in the commercial org is something that we've been emphasizing on almost every call. And I think with each successive call, we have more and more conviction each time on the opportunities that lie ahead of us. And so when COVID first hit, we took a pause and we assessed the areas that we could invest in. We made sure that we had identified properly all the different cost levers and all the different scenarios that this could play out. But now coming out of COVID, coming out of the follow-on offering and the two acquisitions, I don't think that we've had more conviction than we do now that now is the right time to invest for the future. So I think with each successive call, there's more investments that we plan to make. And so it is probably above and beyond what folks have been thinking about in the past.
spk09: And about the capital deployment side on the M&A angle, should we expect a continued cadence of sort of technology platforms?
spk07: So on that question, I would say, you know, our philosophy kind of goes back to starting with technology with the goal of pushing out the frontiers of biology and life sciences generally and kind of working backwards from there in terms of what technology needs to get developed. And as part of that, we think about M&A, again, in that context. We don't have a specific target for acquiring some number of companies every year or every quarter. But in the context of kind of the overarching mission of the company, we certainly see M&A as part of our largest strategy of product development in Malaysia.
spk09: Okay, great. Thanks.
spk11: Thank you. Our next question comes from Doug Shankle with Talon. Your line is now open.
spk01: Hey, good afternoon, guys. So I'm just trying to reconcile a few of your comments. You talked about, you know, I think 35% year-over-year order growth. for Q4, at least, you know, through last week. You indicated that 85% of labs are open but with varying levels of activity. So I'm just trying to, you know, simply put, kind of figure out, you know, how I actually triangulate between these data points and what we should drop into the model. You know, it's important for Q4. It's also important as we kind of think about the trajectory of heading into next year. So could you talk about, you know, specific to orders? Typically, how long does it take for an order to convert? And is there any difference in terms of the patterns you're seeing between capital and consumables? And then simply put, you know, you generated Q3 revenue numbers that were ahead of consensus expectations. Existing consensus, I believe, was for 18% year-over-year growth in Q4 and If I just look at your commentary, which you volunteered on order growth in the quarter, is it fair to say that you are not precisely guiding, but certainly indicating that you're comfortable with a bigger number than what the street was modeling for the fourth quarter?
spk02: Hey, Doug, this is Justin. I'll start with that, and then we'll see if Roger or Serge want to add anything. As far as the 35% year-over-year order growth trend, really what we're doing is just sharing with you what we're currently seeing right now. And that's as of the end of last week, you know, orders are up 35% from where they were a year ago. And that's been pretty stable coming out of the, I guess, coming out of the first couple weeks of Q4. And so, you know, we talked about some of the upsides and downsides that could materialize by quarter end. I do think that there is some danger in just fully extrapolating the 35% over the Q4 2019 revenue, because at the end of the quarter, there's typically this seasonality which results in a large number of orders coming through in the last couple of weeks. And we had that in Q4 of 2019, and we're uncertain to what degree we're going to have that in Q4 of 2020. And so we thought the best that we could do is to share with you what we were currently seeing and then also share with you the risks and opportunities that we see as well.
spk08: Hey, Doug, this is Brad. Maybe just add one of the other parts to your question is you really talked about the sort of sales cycle and the sort of forward-looking visibility. I mean, typically right now our sales cycles are less than six months, obviously, and And as we get involved in maybe some larger orders, some potential moving into clinical studies, those take a lot longer because there's a lot more detail and contractual aspects of them. But overall, roughly about six months. And the only other risk that I would sort of add as we look at the fourth quarter, and we've certainly experienced this, is just moving freight around is a challenge as we go to recognize revenue around the end of the quarter because ultimately, with the restrictions that are in place, and, of course, those are changing. You know, sometimes you just don't have the flights to get stuff shipped out. So that's just one other thing that tempers our forward-looking view of our business.
spk01: Okay, and maybe just one more on these. I think it embedded in my question is, a question about capital versus consumables. In that order number, is there a major difference between capital versus consumables, or is it pretty much the same across the board?
spk08: It's pretty much the same. I mean, obviously, you have a repeat aspect of the consumables, but the only sort of thing I would say is the Chromium Connect at $260,000 has probably a little bit longer sales cycle relative to the way that it has to be approved. But even that, it's it's well within the realm and life sciences of, of, of, you know, that sort of six month timeframe to see orders get through. And in some cases in the U S it's a lot shorter than that.
spk01: Okay. That's helpful. Thank you for all that detail. And then just, just a couple or really just a two parter on read core. I'm just curious if the announcement of that acquisition has had any impact on discussions with, you know, really existing or potential new accounts. And then, you know, in terms of just timelines on the instrument launch, anything you could share on, you know, kind of the earliest we might see something from a new instrument standpoint on a standalone, you know, non-NGS, non-Illumina dependent, you know, sequencing launch via the reCore acquisition.
spk07: So, again, I'll answer the second question first, Doug. Look, we are, as I've indicated, these acquisitions just happened. We are in the process of integrating the teams and the technologies. And so, again, it's too early to talk about any timeframes or even the specs of the products that could come out of this platform. I would reiterate where generally, like, fundamental excited probably, you know, more so than even before we went into the acquisition. So, Overall, we're feeling bullish about the potential and where the platform is going to go. But again, I would caution that at this stage, we're focused on integrating the platform and putting together plans for it and not ready yet to talk about specifics. And I'll let Brad answer the customer dynamic question.
spk08: Yeah, this is interesting because obviously, even generally with Spatial, but certainly within C2, there's a general pull in the market because it's intuitively interesting in the Murphish papers and some things that were out in 2014, 2015. So there's a lot of interest with Cartana has a service business and has had some really interesting research that's been spawned from that. So we're We certainly, customers seem to be excited because there's a view that we can take this technology and give it a 10x experience. And that's something that we're looking forward to doing. But again, a big part of what we're doing right now is just setting expectations. This is way out. But obviously, engaging the customers to understand what they're interested in, what it is about the technology that's going to help them answer pivotal questions in their research.
spk01: Okay, thanks again, guys.
spk11: Thank you. Our next question comes from Patrick Donnelly with Citi. Your line is now open.
spk10: Thanks, guys. Brad, maybe one for you just in terms of kind of the year-end look. You've mentioned a few times, you know, the budget uncertainty going into the end of the year. There's usually that call it budget flush. I guess what have customer conversations been around that? I'm sure you've tried to feel it out a little bit in terms of what customer expectations are going into year ends. We'd love your perspective there. And then if you have it, it might be for you or Justin, just the percentage of revenues that come maybe in that last month of 4Q. I know it's a bit outsized relative to your commentary about 2019. So if you had a ballpark on that, it would be helpful as well.
spk08: All right. So, yeah, let me give you, we got this sort of the end of the quarter impact that's somewhat a result of COVID. We got to see this early because the NIH had their end of the fiscal year at the end of Q3, and we certainly saw a tremendous amount of pent-up spending that couldn't have been consumed or spent while they were out of the labs. And as NIH came back, there was an interest. In fact, we had a large interest on Chromium Connects because a walkaway automation means a lot, and they had money to bring that to a reality. So as we look at the end of the fourth quarter, we have a lot of customers now that have moved, let's say, past the idea of getting back in the lab and now are really trying to make up for lost time. And lost time in some cases is spending money so they don't lose it. And this might be more of an evidence even in pharma. We're seeing a lot of interest in biopharma who have budgets that they want to consume to balance their year-over-year spend. In general, I think people now, I actually, to be quite honest with you, I think this was slower than I expected back in early May. I thought once the lab started open, it would just move very quickly. It certainly took a lot, lot longer in most of, you know, Q, well into early part of Q3. But now we've really seen that sort of let's get back, let's get, you know, people are competitive, get papers out, you know, postdocs, people finishing research. So that's, I hesitate at all to say business as usual, but it does tend to more of a dynamic in the market.
spk02: Hey, Patrick. This is Justin. I'll take the second part. We haven't shared before a percent that would fall in the final weeks, but I can tell you that typically we see the orders pick up around the second week of December and carry through the end of the year.
spk11: Thank you. Our next question comes from David Westenberg with Guggenheim Securities. Your line is now open.
spk05: Hey, guys. Thanks for taking the question. I just want to continue with that concept. And sorry, I asked a very similar question on last calls. But, you know, as we're going back and we looked at our models, you know, last year, you know, labs are opening a little slower than usual. But wouldn't 2021 look like what we originally thought 2020 would look like but with some added pent-up demand? And, you know, as we go out into 2021, Our 2022, I mean, shouldn't that look relatively the same? Now, I get that, you know, we always have second wave of COVID, but as the same, you know, as we've discussed, NIH funding is exactly the same. And I realize that you guys have to be a little bit conservative here, but, you know, it seems like your customer base is almost exactly the same. the reception of your product from your customer base looks pretty much actually maybe even ahead of what we thought to begin the year.
spk07: There's a lot of questions embedded in that, David. I would say if your question is around what does 2021 look like and whether it's sort of bouncing back to what the year would have been without COVID, I think that would be I'm certainly pretty much sure to view it that way because there's also quite a bit of essentially lost time that happened in 2020, right, if you think about sort of research and customer dynamics. There's probably less placements. Yeah, so I mean, the reduced placements, people who have not run the experiments And some of those experiments, certainly there is some amount of pent-up demand, but there's certainly some experiments that are just sort of gone. So I don't think you can sort of just kind of imagine the bounce back completely to the way it would have been otherwise, because we have lost some time.
spk05: Okay. All right, I'll move on maybe to follow up with you a little bit offline on that. Just in terms of sizing the TAM for ReadCore, you know, I appreciate that this is going to take a little bit of time, but do you feel like when you size the TAM for the acquisition, Did you use the volume that you'd see in, say, fish IHC and just kind of apply a premium to that in terms of how we size the market? Because to me, it seems like this is a little bit beyond the reach of sequencing and more on the... the microscopy market, but with a plus premium to it. And then in terms of sticking with FIST and SEEK, you know, you've locked up a lot of technologies with this. Do you feel like, you know, with all the patents you've acquired, you've pretty much locked up FIST-SEEK as a spatial technology? Thank you.
spk07: So I would say in terms of sizing the market, I think you're on the right track. I mean, that's certainly how we've looked at things. for sure. I think there's, again, the potential of this market is quite enormous because, again, you're bringing a lot more content and information that could be extracted from these samples. So in terms of locking up fistic, yes, I mean, for sure, but I would say it's more broadly than that because this idea stays covered in situ more broadly than just fistic, but kind of all the other major approaches as well.
spk00: Thank you.
spk11: Thank you. Our next question comes from Dan Arias with Steeple. Your line is now open.
spk03: Hey, guys. Good afternoon. Serge or Brad, for new Visium customers, are you guys able to ship product to the lab and then have them get up and running through a remote support effort, or do you find that there's generally some in-person hand-holding that's needed there? I'm just wondering if the lack of an install and training need is It's kind of proving meaningful for you guys in the current environment, access restrictions and such.
spk08: This is Brad. I'll take that. So with Visium, we never, given that we contemplated a much wider use case, given there was a relatively low barrier to entry, obviously no instrument, we actually planned to do this entirely virtually, and we built the tools to do that. So it really hasn't changed anything. So we're able to onboard customers. We do that with a fairly extensive, usually multi-part hours of sort of online steps or training that the customer goes through on a self-paced level. And then we actually have an FAS that will engage them, again, now virtually over almost a full day, just making sure we get them up. And then we obviously follow them as they adopt the technology over the coming weeks.
spk03: Okay, helpful. And then maybe just, can I ask about some color on the V2 immune profiling kit? Where are you seeing initial traction? I'm not sure if you want to put a dollar amount on what you're seeing there, though I would certainly listen if you did. But can you just sort of help us maybe with some context on the contribution potential versus some of your other assays or kits, and maybe whether we should think about 4Q contributions being up quarter over quarter, just given the pace of COVID work, et cetera? Thanks.
spk08: Well, yeah, I mean, you stuck on did it have a particular utilization, obviously infectious disease, but in general, our immune profiling product has been growing quite nicely as, again, has a lot of applications. But in general, I think that what we saw in this quarter was The fact that, and I was alluded to, or Serge alluded to it, that we had people that immediately, that had been using version one for a long time, immediately transitioned to version two without any sort of testing. And we saw a little bit of that when we did the same thing with our expression, our gene expression product. But I think people now, and a lot of them are the same customers, have trusted the fact that the product would work accordingly. And it does give them a lot more sensitivity but then also the flexibility that if they want to save on sequence and they can do it too. It's again exactly the same thing we had with gene expression. The other thing that's important about this is that we had been very reluctant to move some of our legacy GEM, again in immune profiling, onto NextGEM because we knew we had this version two coming and we didn't want to push them down a path of making a switch and then taking that product away from them. Now that we've done this, this really clears the way so that we can be essentially a hundred percent cut over from legacy gem by the end of the year.
spk03: Okay. And then if I could just stick one more quick in there, maybe for surge, just on in situ within the body of work that exists today is the focus more RNA, DNA, or protein. I'm sure it's mixed, but I'm just sort of curious about where the foundation is being laid or has been laid there.
spk07: Yeah, I don't think we're ready to talk about this yet. I mean, most of the work, if you look at what the companies have actually shown data for and worked on, tends to be RNA-focused. But as far as what we're planning for the future, that's too early to talk about.
spk03: Okay, got it. Thank you.
spk11: Thank you. And our next question comes from Tejas Savant with Morgan Stanley. Your line is now open.
spk04: Hey guys, good evening. So just going back to the COVID impact question, Brad, can you talk about sort of any specific pockets of impact from the resurgence, especially in Europe? One of your competitors called out a little bit of a headwind there. And I think you mentioned earlier sort of shipping and freight issues, particularly across borders and so on. So I was wondering if you were actually seeing signs of that, or is that just something that could happen, and hence you're being a little bit conservative in terms of framing the fourth quarter here?
spk08: All right. So as far as the headwinds, obviously we're watching this, and a lot of this is very on a daily basis. But so far we just have not seen, as I said earlier, maybe that we are seeing any labs shut down or close. And in fact, I think over time, the efficiency of people learning how to work in a reduction. See, a lot of the times we're using labs, we say labs at 25%. That just means that only 25% of people can be in that lab at any one time. They're able to use rotations and get back up to some reasonable capacity. So we continue to see that happening, as Justin's already described that. In terms of around a given quarter, it's always a challenge. There's always a challenge sometimes in moving product out. We'd love our customers to order earlier. The end of the quarter push is there. And then, yeah, we definitely, at the end of Q2 and certainly the end of Q3, had to be a lot more careful in planning shipments And as much to make sure that we meet our commitments to our customers. So I don't think there's anything hugely acute with fourth quarter. I'm hoping that it won't be any worse than what we experienced. I think Q2 was probably the biggest challenge of the Q2 to Q3. But it's just something we've got to be well aware of as a risk.
spk04: Got it. That's helpful. And then in terms of what you're seeing out of Asia, I mean, specifically China, I mean, I think it's high teen sort of revenue exposure for you, if I'm not mistaken. Can you just walk us through the pace of the recovery and the path to normalization specifically in China?
spk08: Yeah, you know, it's amazing. China's gone almost, I would say, sort of effectively bankrupt. 100% in the context of the fact that people are opening. Our labs are open. We're making sales calls. People are going to conferences. And so that is good. There is a little bit of a disrupt in the funding as the government repositions so they can do sort of massive testing when they deal with some of these outbreaks. But in general, we feel like China's kind of reached back to where it was ahead of the COVID, which was about a year ago, if you think about it.
spk04: Got it. And then one final one on Chromium ASPs here. Justin, in the past, you've spoken about sort of a degree of discounting with larger consumables purchases. How should we think about that specific driver of the model for you when we sort of juxtapose it with the Chromium Connect launcher? Obviously, it comes with higher ASPs. And I think on an earlier call, you guys had mentioned sort of the walkaway automation being particularly attractive during the pandemic. So how do we balance sort of those two opposing forces as we think about ASPs over the medium term here?
spk02: Yeah, so for ASPs, we had talked about in the past how during Q2, we gave deeper discounts primarily related to sales where the instrument was going to be used in COVID research. And historically, we have given larger discounts when it's attached to a larger consumable order. But if we look at just the chromium controller by itself, the ASP actually increased from Q2 to Q3 because a smaller percent of our business was driven by COVID sales. But then when you combine and calculate an ASP off of the Chromium Connect and the regular Chromium Controller. Obviously, with the list price that's in the mid-200s for the Chromium Connect, that's going to bring the ASP up. But still, when you look at the overall percent of the Chromium Connect, overall percent of all instruments sold, it's still a relatively small number. So it does have some impact, and we're still basically staying within the range that we were near the range that we've talked about in the past in the $50,000 to $55,000 range on a blended basis.
spk04: Got it. Appreciate the color, guys. Thanks.
spk11: Thank you, and I'm showing no further questions in the queue at this time. Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.
Disclaimer